Considering the increased risk of HCC in patients with T2DM and the fact that SGLT2 is expressed on certain cancer cells including HCC and canagliflozin has been reported to inhibit the growth of hepatoma cells, it is expected that the opportunity for combined use of canagliflozin and sorafenib/lenvatinib in clinical practice will continue to increase in the future. This evidence concerns the gene SLC5A2 and cancer.